Colleen Kane
Janssen Pharmaceutica
17 Papers
8 Citations
Colleen Kane is an academic researcher from Janssen Pharmaceutica. The author has contributed to research in topics: Daratumumab & Medicine. The author has an hindex of 3, co-authored 11 publications.
Chat about Author
Papers
Fusion to a highly stable consensus albumin binding domain allows for tunable pharmacokinetics
TL;DR: The engineering of a novel albumin binding domain (ABD) three-helix bundle protein, called ABDCon, is described, which binds human, monkey and mouse serum albumins with affinity as high as 61 pM and is highly stable.
GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review
Paula Rodriguez-Otero,N. W. van de Donk,Kodandaram Pillarisetti,Ingrid Cornax,Deeksha Vishwamitra,Kathleen Gray,Brandi Hilder,Jaszianne A. Tolbert,Thomas Renaud,Tara Masterson,Christoph Heuck,Colleen Kane,Raluca I. Verona,P. Moreau,Nizar Bahlis,Ajai Chari +15 more
TL;DR: Results from early phase trials of GPRC5D-targeting T-cell–redirecting agents have shown promising efficacy and manageable safety profiles, including lower infection rates compared with B-cell maturation antigen- and Fc receptor-like protein 5-targeting bispecific antibodies.
27
Inhalation Delivery of Protein Therapeutics
TL;DR: A background into efforts to develop inhaled biological therapies is provided and some of the associated challenges are highlighted and the ideal properties of a biologic therapy for inhaled delivery are speculated on.
18
Daratumumab Plus Atezolizumab in Previously Treated Advanced or Metastatic NSCLC: Brief Report on a Randomized, Open-Label, Phase 1b/2 Study (LUC2001 JNJ-54767414)
Rathi N. Pillai,Suresh S. Ramalingam,Meena Thayu,Patricia Lorenzini,Diana A. Alvarez Arias,Christopher Moy,Natalie Hutnick,Roland Elmar Knoblauch,Huaibao Feng,Colleen Kane,Leora Horn,Martin Reck,Santiago Ponce +12 more
- 01 Feb 2021
TL;DR: Daratumumab plus atzolizumab therapy did not improve efficacy versus atezolizumsab monotherapy for patients with previously treated advanced NSCLC.
11
CULMINATE: A phase II study of cusatuzumab + azacitidine in patients with newly diagnosed AML, ineligible for intensive chemotherapy.
Geralyn Carol Trudel,Angela Howes,Neelum Jeste,Jeffrey J. Tryon,Liang Xiu,Colleen Kane,Kerri Nottage +6 more
TL;DR: The once-in-a-lifetime opportunity to evaluate the progenitor cells of hematopoietic progenitors in patients with acute leukaemia and decide whether or not to treat them with chemotherapy or radiation is important.
10